Nanobody-based CD5-targeted CAR-T cells

Nanobody-based CD5-targeted CAR-T cells are an investigational chimeric antigen receptor (CAR) T-cell therapy developed by Peking University People's Hospital for the treatment of relapsed or refractory T-cell malignancies. This therapy utilizes a nanobody-derived antigen-binding domain to target CD5, a 67-kDa transmembrane glycoprotein expressed on the surface of most mature T cells and malignant T cells in T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). By engineering a patient's own T cells to express this CD5-specific CAR, the therapy aims to induce targeted cytotoxicity against CD5-positive tumor cells. The use of nanobodies, which are single-domain antibody fragments, is intended to improve the stability and specificity of the CAR construct while potentially reducing tonic signaling compared to traditional scFv-based designs. The therapy is currently being evaluated in the Phase I/II CONQUER clinical trial.

Other names

Nanobody-Based CD5-Targeted CAR-TCONQUER CAR-T